Virtual reality could help measure and treat cancer pain, study suggests
NCT ID NCT06456411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer patients. The goal was to develop new tools for pain assessment and non-drug pain relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Virtual reality relaxation program
- What this could lead to
- If successful, this could lead to better, non-drug ways to measure and manage cancer pain, potentially reducing reliance on painkillers.
- What could go wrong
- The study was terminated early, so results are limited. It was also a small, early-stage study, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
106 people
The number who actually took part.
- Started
-
Jul 2022
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: GROUPS A, B and C: * Cancer pts as well as healthy volunteers) must be over the age of 18 * Participants in Groups A or C (cancer pts as well as healthy volunteers) need to be able to be in a sedentary posture for approximately 20 minutes * Participants in Group B and C: Patient can be in any stage of cancer treatment, such as diagnosis, treatment (surgery, chemotherapy, immunotherapy, radiation), recovery, remission and is experiencing acute pain from treatment or cancer itself. Cancers include but are not limited to: breast, thoracic, lung, kidney, colon, pancreatic, etc. * Participants in Group B and C must be free from other forms of chronic pain, e.g., rheumatologic pain, must be free from neurologic illnesses, e.g., stroke, and must have no brain metastases which could interfere with brain functions * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Inclusion Criteria - GROUP D: * Men and women of 40-80 yrs old * Stage I-III lung cancer survivors who have undergone lung resection and developed persistent post-thoracotomy pain (PPTP) * Willing to comply with study procedures * Be able to remain sedentary for 20 minutes during functional near-infrared spectroscopy (fNIRS) data recording sessions, including 10 minutes each for fNIRS system setup and 10 minutes data recording. * Female participants must not be pregnant to participate in this study. During the third trimester, the fetus's brain is significantly developed and may interact with the mother's brain. As this study involves recording brain activity using fNIRS, it is necessary to exclude pregnant individuals to ensure the quality of the research data. * Be able to remove any items from their scalp that might block direct contact between the fNIRS optodes and the skin. This includes, but is not limited to, wigs and hijabs. * Must be free from other forms of chronic pain, e.g., rheumatologic pain * Must be free from neurologic illnesses, e.g., stroke * Had no brain metastases which could interfere with brain functions * Must understand the investigational nature of the study and sign a written informed consent form approved by the Independent Ethics Committee/Institutional Review Board. Inclusion criteria for Group E: * Men and women aged 18 yrs and older. * Diagnosed with colorectal or pancreatic cancer, scheduled to receive a 14-day cycle of oxaliplatin chemotherapy (oxaliplatin plus infusional fluorouracil regimens). Limiting the study to these patients ensures a more uniform population, reducing variability related to treatment regimens. * Be able to remove any items from their scalp that might block direct contact between the skin and fNIRS optodes. This includes, but is not limited to, wigs and hijabs. Furthermore, individuals with metal implants in the skull due to previous surgeries are not eligible to participate. * Participants must be willing to comply with study procedures. * Must understand the investigational nature of the study and sign a written informed consent form approved by the Independent Ethics Committee/Institutional Review Board. Exclusion Criteria - GROUPS A, B and C: * Unwilling or unable to follow protocol requirements * Currently pregnant or planning to become pregnant during the study period FOR GROUP B : * Medical condition predisposing to nausea or dizziness. * Hypersensitivity to flashing light or motion. * stereoscopic vision or severe hearing impairment. * Unwillingness or inability to follow protocol requirements. * Individuals with impaired decision-making capacity. * Individuals with electronic or metallic implants in the head. * Unable to remove any items from their scalp that might block direct contact between the fNIRS optodes and the skin. This includes, but is not limited to, wigs and hijabs * Prisoners Exclusion criteria for Group D * individuals with hypersensitivity to flashing lights or motion. Rationale: Such hypersensitivities can increase the risk of seizures or severe discomfort when exposed to common elements of VR programs, which frequently include rapid visual and motion stimuli. * individuals with impaired stereoscopic vision or severe hearing impairments. Rationale: VR programs often involve moving objects, flashing lights, and immersive soundscapes. Participants must have sufficient vision and hearing to effectively engage with and safely navigate these environments. * Currently pregnant or planning to become pregnant during the study period. * Unwillingness or inability to follow protocol requirements. * individuals with impaired decision-making capacity. Rationale: Participants must be able to provide informed consent and make decisions regarding their continued participation in the study. * Prisoners * Individuals with electronic or metallic implants in the head, as these implants may obstruct direct contact between the fNIRS optodes and the skin. * Patients with medical conditions that predispose them to nausea or dizziness. Rationale: To minimize the risk of cybersickness that may be induced by VR programs. * Patients with signs of cancer-related cachexia, specifically those with \>15% unintentional weight loss over the past 6 months or a BMI \<18 will be excluded to ensure safety and data integrity. * Diabetic patients are excluded as they may experience chronic pain differently. Exclusion Criteria for Group E * Individuals treated with Carboplatin, Cisplatin, taxanes, or other platinum-based therapies should be excluded. These treatments are known to cause peripheral neuropathy, and their inclusion could confound the results. To focus specifically on neuropathy caused by oxaliplatin, patients receiving other neurotoxic chemotherapy agents are excluded. * Individuals who underwent other neuropathy-associated chemotherapy treatments will be excluded. * Females who are pregnant or plan to become pregnant during the study period will be excluded. * Unwillingness or inability to follow protocol requirements. * individuals with impaired decision-making capacity. Rationale: Participants must be able to provide informed consent and make decisions regarding their continued participation in the study. * Individuals who are not yet adults (younger than 18 years). * Prisoners. * Individuals with electronic or metallic implants in the head, as these implants may obstruct direct contact between the skin and fNIRS optodes. * Pre-existing conditions or comorbidities that could interfere with the study, such as: * severe neurological disorders, neurologic illnesses, e.g stroke * peripheral neuropathy unrelated to chemotherapy * other forms of chronic neuropathy * diabetic patients will be excluded as those patients may experience different neuropathy and their reactions might skew the results
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- Can a blood test before pancreatic surgery predict a dangerous leak?
- Burning the edges: a new way to stop colon polyps from coming back
- New chemo cocktail targets pancreatic cancer at every stage
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?